Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Nemtabrutinib - Merck

Next Previous
Drug Profile

Nemtabrutinib - Merck

Alternative Names: ARQ-531; MK-1026

Latest Information Update: 13 May 2026

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator ArQule
  • Developer Merck & Co
  • Class Antineoplastics; Pyrimidines; Pyrroles; Small molecules
  • Mechanism of Action Agammaglobulinaemia tyrosine kinase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Chronic lymphocytic leukaemia
  • New Molecular Entity Yes

Highest Development Phases

  • Phase III Chronic lymphocytic leukaemia
  • Phase II Follicular lymphoma; Haematological malignancies; Richter's syndrome

Most Recent Events

  • 29 Apr 2026 Merck Sharp & Dohme in collaboration with Ohio State University Comprehensive Cancer Center plans a phase II trial for Chronic lymphocytic leukaemia in USA in May 2026 (PO)(NCT07557056)
  • 28 Mar 2026 No recent reports of development identified for phase-I development in Haematological-malignancies(Second-line therapy or greater) in Japan (PO)
  • 04 Mar 2026 Efficacy and adverse event data from the phase II BELLWAVE-003 trial in Follicular lymphoma presented at the 67th American Society of Hematology Annual Meeting and Exposition (ASH-Hem-2025)

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top